Evidence map›Paper›PMID 26178718›Full record

ArticleBiology of reproduction2015

Developmental Programming: Does Prenatal Steroid Excess Disrupt the Ovarian VEGF System in Sheep?

Hugo Héctor Ortega, Almudena Veiga-Lopez, Shilpa Sreedharan, Melisa María del Luján Velázquez, Natalia Raquel Salvetti, Vasantha Padmanabhan

Open access · bronzeAbstract read
In one paragraph

Article in Biology of reproduction, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Hugo Héctor OrtegaDepartment of Morphological Sciences, Faculty of Veterinary Sciences, National University of Litoral, Esperanza, Santa Fe, Argentina Argentine National Research Council (CONICET), Esperanza, Santa Fe, Argentina.
Almudena Veiga-LopezDepartment of Pediatrics and the Reproductive Sciences Program, University of Michigan, Ann Arbor, Michigan.
Shilpa SreedharanDepartment of Pediatrics and the Reproductive Sciences Program, University of Michigan, Ann Arbor, Michigan.
Melisa María del Luján VelázquezDepartment of Morphological Sciences, Faculty of Veterinary Sciences, National University of Litoral, Esperanza, Santa Fe, Argentina Argentine National Research Council (CONICET), Esperanza, Santa Fe, Argentina.
Natalia Raquel SalvettiDepartment of Morphological Sciences, Faculty of Veterinary Sciences, National University of Litoral, Esperanza, Santa Fe, Argentina Argentine National Research Council (CONICET), Esperanza, Santa Fe, Argentina.
Vasantha PadmanabhanDepartment of Pediatrics and the Reproductive Sciences Program, University of Michigan, Ann Arbor, Michigan vasantha@umich.edu.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of Michigan–Ann Arbor · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
STEROIDAL AND METABOLIC MEDIATION OF NEUROENDOCRINE CIRCUITRYP01HD044232 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROWN, MORTON B. · 2004 to 2015
$12.9M
NICHD NIH HHS P01 HD044232NICHD NIH HHS P01-HD44232NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

Prenatal testosterone (T), but not dihydrotestosterone (DHT), excess disrupts ovarian cyclicity and increases follicular recruitment and persistence. We hypothesized that the disruption in the vascular endothelial growth factor (VEGF) system contributes to the enhancement of follicular recruitment and persistence in prenatal T-treated sheep. The impact of T/DHT treatments from Days 30 to 90 of gestation on VEGFA, VEGFB, and their receptor (VEGFR-1 [FLT1], VEGFR-2 [KDR], and VEGFR-3 [FLT4]) protein expression was examined by immunohistochemistry on Fetal Days 90 and 140, 22 wk, 10 mo (postpubertal), and 21 mo (adult) of age. Arterial morphometry was performed in Fetal Day 140 and postpubertal ovaries. VEGFA and VEGFB expression were found in granulosa cells at all stages of follicular development with increased expression in antral follicles. VEGFA was present in theca interna, while VEGFB was present in theca interna/externa and stromal cells. All three receptors were expressed in the granulosa, theca, and stromal cells during all stages of follicular development. VEGFR-3 increased with follicular differentiation with the highest level seen in the granulosa cells of antral follicles. None of the members of the VEGF family or their receptor expression were altered by age or prenatal T/DHT treatments. At Fetal Day 140, area, wall thickness, and wall area of arteries from the ovarian hilum were larger in prenatal T- and DHT-treated females, suggestive of early androgenic programming of arterial differentiation. This may facilitate increased delivery of endocrine factors and thus indirectly contribute to the development of the multifollicular phenotype.

Indexed as

AnimalsDihydrotestosteroneFemaleFetal DevelopmentImmunohistochemistryNeovascularization, PhysiologicOvaryPregnancyRegional Blood FlowSheep, DomesticSteroidsTestosteroneVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2DihydrotestosteroneSteroidsTestosteroneVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ovaryPCOSsheeptestosteroneVEGF

Identifiers

PMID26178718
PMCPMC4710184
OpenAlexW2179681279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.